Clinical trials: Hepatoma
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC)…
- Trial name
- NCT06553885
- Testing
- Enfortumab Vedotin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Liver Cancer, Hepatitis B
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection.
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver
- Trial name
- NCT00767936
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Stanford University
Cirrhosis, Hepatocellular Carcinoma
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of a high dose of vitamin D (VD) in patients with cirrhosis.
- Trial name
- NCT01956864
- Testing
- Vitamin D
- Where
- United States
- Sponsor
- Johns Hopkins University
Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
This is a single-center, single-arm, open-label Phase I study to evaluate the safety and efficacy of GPC3-CAR-T cell immunotherapy in the treatment of hepatocellular carcinoma.
- Trial name
- NCT05344664
- Testing
- GPC3-CAR-T cells
- Volunteers
- 12 people
- Sponsor
- Peking University
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Inoperable HCC
Hepatocellular Carcinoma (HCC)_Torisel_
This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel
- Trial name
- NCT01251458
- Testing
- Torisel
- Where
- Hong Kong
- Volunteers
- 46 people
- Sponsor
- Chinese University of Hong Kong
HCC - Hepatocellular Carcinoma, Diabetes
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in…
- Trial name
- NCT07557914
- Testing
- Epalrestat, Donafenib + Tislelizumab, HAIC
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Haibo Shao
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients…
- Trial name
- CCGLC-017 (NCT06954116)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tongji Hospital
Liver Resection
Application of Watson for Oncology in Hepatocellular Carcinoma Surgery
The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.
- Trial name
- NCT03904667
- Testing
- Watson on oncology surgery decision evaluation
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhujiang Hospital
Liver Metastases, Colorectal Cancer Metastatic
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in…
- Conditions
- Liver Metastases, Colorectal Cancer Metastatic, Liver Neoplasm, Neoplasms
- Trial name
- COLT (NCT03803436)
- Testing
- Liver transplant, Chemotherapy
- Where
- 12 sites in Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma (HCC)
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
- Trial name
- RAD 0902 (NCT01247298)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Hepatocellular Carcinoma
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07157306
- Testing
- Gecacitinib Combined With Donafenib and PD-1 Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cancer, Liver Tumor
Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)
This is a study following the outcomes and survival of patients undergoing the TAMLAPS hepatectomy at Florida Hospital Tampa by Dr. Iswanto Sucandy
- Conditions
- Liver Cancer, Liver Tumor, Hepatocellular Carcinoma, Hilar Cholangiocarcinoma
- Trial name
- TAMLAPS (NCT03739164)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Florida Hospital Tampa Bay Division
Pancreatic Ductal Adenocarcinoma, Liver, Cancer of, Primary Resectable
Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery
The goal of this study is to assess the efficacy of intraoperative celiac plexus block (CPB) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery
- Trial name
- CEBOIDS (NCT06214533)
- Testing
- Ropivacaine 0.5%, Normal Saline
- Volunteers
- 60 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hepatocellular Carcinoma
PAtient-PHYsician Relationship Assessment
I) Introduction Patients with cancer face difficult choices that require balancing competing priorities such as survival, functional capacity and symptom relief.
- Trial name
- PAPHYRA (NCT05729230)
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Erasme University Hospital
Unresectable Hepatocellular Carcinoma
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
- Trial name
- ABH-uHCC (NCT07806292)
- Testing
- anlotinib combined with benmelstobart and HAIC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma (HCC)
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
- Trial name
- NCT03516071
- Testing
- Brivanib 800 mg, QD, Brivanib 400 mg, BID
- Where
- 15 sites in China
- Volunteers
- 90 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Cholangiocarcinoma, Liver Cancer
Evaluation of Stereotactic Radiosurgery For Liver Malignancies
This study is intended to establish the practicality of treating cancer in the liver with precisely administered single fractions of high-energy radiation using a radiosurgical (cross-firing) technique.
- Conditions
- Cholangiocarcinoma, Liver Cancer, Adenocarcinoma
- Trial name
- NCT00230347
- Testing
- Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Liver Cancer
Vaccine Therapy in Treating Patients With Liver Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00022334
- Testing
- AFP
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.